Clinical trial
A PHASE 2, OPEN-LABEL STUDY OF IRPAGRATINIB IN COMBINATION WITH ATEZOLIZUMAB AND BEVACIZUMAB IN PATIENTS WITH ADVANCED OR UNRESECTABLE HEPATOCELLULAR CARCINOMA (IAPETUS)
NCT07010497 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A PHASE 2, OPEN-LABEL STUDY OF IRPAGRATINIB IN COMBINATION WITH ATEZOLIZUMAB AND BEVACIZUMAB IN PATIENTS WITH ADVANCED OR UNRESECTABLE HEPATOCELLULAR CARCINOMA (IAPETUS)
- Lead sponsor
- Asan Medical Center
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- March 16, 2026
- Completion date
- March 31, 2029
- Enrollment
- 33 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.